Study published in The Lancet shows new treatment for later stage multiple sclerosis significantly improves outcomes

Novartis has announced that the full results from the EXPAND study of siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS) were published in The Lancet.

These results show significant reductions in the risk of three and six-month disability progression with siponimod versus placebo and favourable outcomes in other relevant measures of MS disease activity.